Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $130
Grail Inc GRAL
$125.11
▼ -2.32%
($-2.97)
🎢 High Beta
Open
$127.49
Prev Close
$128.08
Day Range
$121.00 – $127.70
52W Range
$41.50 – $166.48
Market Cap
$5.76B
Beta
1.98
EPS (TTM)
$-9.75
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-06-12 |
| Shares Out. | 44,670,000 |
| Website | grail.com/ ↗ |
| Phone | 13026587581 |
| Employees | 910 |
| Revenue | $44.7M |
| Gross Profit | -$12.6M |
| Net Income | -$110.2M |
| Free Cash Flow | -$296.2M |
| Total Assets | $2.84B |
| Total Liabilities | $301.0M |
| Equity | $2.54B |
About Grail Inc
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Grail Inc is a publicly traded company under the ticker symbol GRAL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
18 analysts (2026-11-01)
📰 Latest News for GRAL
GRAIL Inc (GRAL) (Q3 2026) Earnings Call Highlights: FDA Nod on the Horizon as Galleri Gains ...
A Bloody Bad Time: Grail Gutted On Light Blood Test Sales
Is GRAIL (GRAL) Fully Valued As Fresh Earnings Reignite Questions Over Galleri?
GRAIL (GRAL) Q3 2026 Earnings Call Transcript
RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100
GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth
GRAIL, Inc. Q3 2026 Earnings Call Summary